Comparability between early and late dapagliflozin administration for decompensated coronary heart failure
Sodium-glucose cotransporter 2 inhibitors have demonstrated constructive results in coronary heart failure (HF) sufferers. Nevertheless, the results of dapagliflozin in sufferers with decompensated HF stay unclear. This research aimed to ...
